← All trials
NCT05074966
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 6, 2021
- Primary completion
- Jun 24, 2024
- Completion date
- Jun 24, 2025
- First posted
- Oct 12, 2021
- Last posted
- Oct 12, 2021
- Enrollment
- 314
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Chinese Academy of Medical SciencesReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.